Summersalt Launches International Shipping
18.8.2021 14:01:00 EEST | Business Wire | Press release
Expanding Summersalt’s footprint globally, today the brand announces plans to introduce international shipping to over 180 countries in over 120 different currencies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210818005211/en/
Summersalt’s 2021 “Everybody is a Summersalt Body” campaign (Photo: Business Wire)
Summersalt will launch globally with shipping to Canada, the United Kingdom, India, Australia, Africa, Asia, Europe, South America and more. International customers will be offered a localized check out experience based on their respective currency, language and payment preferences, as well as guaranteed customs, duties and shipping calculations.
“Launching internationally is a logical next step as we strategically build upon Summersalt’s growth domestically and as demand for the brand accelerates worldwide,” said Lori Coulter, CEO, President and Co-founder of Summersalt. “As a digitally native brand, we are excited to expand our reach into new markets and to offer a seamless online shopping and returns experience to Summersalt’s international community.”
“Our customer is a global citizen who loves to travel and explore, and has been requesting Summersalt via every channel since launch day. We are thrilled to offer Summersalt around the world,” said Reshma Chattaram Chamberlin, Chief Digital Brand Officer and Co-founder of Summersalt.
Summersalt was founded on a mission to bring back the childlike joy of wearing a swimsuit by offering designer-quality swimwear at an affordable price. Summersalt offers not only swimwear, but loungewear, activewear, sweaters, pajamas, intimates and more in sizes 0-24.
International expansion plans come on the heels of Summersalt’s highly celebrated “Everybody is a Summersalt Body” campaign, which featured 24 incredible and diverse women, and was centered around joy and self-expression, aiming to empower women to feel good about themselves.
About Summersalt
Summersalt is a generation-defining apparel brand, providing wardrobe essentials for women who are going places. Summersalt launched in 2017 with swimwear made from recycled materials at a $95 price point — designer quality swimwear without the designer price tag. Since then, we’ve launched additional categories including loungewear, knitwear, sleepwear, intimates and activewear. Summersalt pieces are modern, sophisticated and fun, with an impeccable data-backed fit based on millions of measurements from over 10,000 women. In the few short years since our founding, Summersalt has built a loyal following of customers, influencers and celebrities, while garnering praise from leading fashion media including Vogue, Harper’s Bazaar, ELLE and InStyle. In 2019, Summersalt was included in CNBC’s Upstart 100 list and also named one of Fast Company’s Most Innovative Companies in 2020.
To learn more about Summersalt, visit summersalt.com or follow the brand on Instagram and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210818005211/en/
Contact information
Amanda Jacobs
Email: summersalt@azionepr.com
Phone: 646-490-2945
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datavault AI Announces Board of Directors Has Requested Management’s Complete Plan for Dividend Spin-Out of Acoustic Sciences Division into Stand-Alone Public Company7.5.2026 16:07:00 EEST | Press release
Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a pioneering technology licensing company seeking to redefine data valuation, monetization, and secure Web 3.0 experiences, today announced that Company management has commenced its evaluation of a potential dividend spin-out of the Company’s Acoustic Sciences division which includes its ADIO®, WiSA®, Event Citadel™, and API Media operations into a new stand-alone public company, which is proposed to be named “API Media”. The Company has reserved the ticker symbol “ADIO” for the proposed spin-out entity and currently intends that API Media will be listed on NASDAQ following completion of the proposed transactions, which remain subject to approval by the Company’s board of directors, definitive agreement, and satisfaction of closing conditions, as well as any regulatory approvals that may be required in connection therewith. The Company has engaged Houlihan Lokey as its financial advisor and Paul Hastings LLP as its lega
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura ® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 15:50:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs). These data were presented (Abstract ID: P0851) today at the 2026 European Academy of Dermatology and Venereology (EADV) Symposium, being held May 7–9, 2026, in Athens, Greece. As previously reported, the TRuE-AD4 study met both of its co-primary endpoints at Week 8, with a statistically significantly higher proportion of patients on Opzelura versus vehicle cream achieving EASI75 (≥75% improvement in Eczema Area and Severity Index score from baseline) and, separately, IGA-TS (Investigator's Global Assessment Treatment Success, defined as an IGA score of 0 [clear] or 1 [almost clear] with at least a two-point improvement from baseline).1 Patients who
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 15:03:00 EEST | Press release
Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L. Saver, MD, UCLA, and Principal Investigator of DISTALS. “What’s important is that both the device and the trial were designed specifically for distal stroke. By using a device built for these small vessels and mea
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 15:00:00 EEST | Press release
Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have faced two critical dining pain points: [Pain Point 1] The Information Gap: Most available resources are tailored for tourists, making it difficult to find the true loc
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 15:00:00 EEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom